Sichuan Kelun Pharmaceutical (002422.SZ): Luchipobapapai tablets obtained drug registration approval.

Sichuan Kelun Pharmaceutical (002422.SZ) announced that their chemical drug "Luzhu Bopapine" has recently received approval for drug registration from the National Medical Products Administration. Luzhu Bopapine is a new generation of oral small molecule thrombopoietin receptor agonist (TPO-RA) developed by Yamanouchi, first launched in Japan in 2015, approved for import in China in 2023, used for adult patients with chronic liver disease accompanied by thrombocytopenia planning to undergo surgery (including diagnostic procedures).